Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: Evidence from 96 studies

European Journal of Human Genetics

Volumn 17, Issue 12, 2009, Pages 1668-1675

  Chen, Wensen ^a,b   Wang, Sumin ^a   Tian, Tian ^a   Bai, Jianling ^a   Hu, Zhibin ^a   Xu, Yan ^a   Dong, Jing ^a   Chen, Feng ^a   Wang, Xinru ^a   Shen, Hongbing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Center for Disease Control and Pevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLORECTAL CANCER; GENETIC ASSOCIATION; GENOTYPE; HUMAN; PHENOTYPE; PREMENOPAUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; NEOPLASM STAGING; NEOPLASMS; PHENOTYPE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; PUBLICATION BIAS; RISK FACTORS;

EID: 70450255319     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2009.86     Document Type: Article

References (57)

1. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215-244.
2. Pollak M: Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000; 36: 1224-1228.
3. Furstenberger G, Senn HJ: Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302.
4. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M: Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353.
5. Lacey Jr JV, Potischman N, Madigan MP et al: Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: Results from a US case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13: 607-612.
6. Hong Y, Pedersen NL, Brismar K, Hall K, de Faire U: Quantitative genetic analyses of insulin-like growth factor I (IGF-I), IGF-binding protein-1, and insulin levels in middle-aged and elderly twins. J Clin Endocrinol Metab 1996; 81: 1791-1797.
7. Tae HJ, Luo X, Kim KH: Roles of CCAAT/enhancer-binding protein and its binding site on repression and derepression of acetyl-CoA carboxylase gene. J Biol Chem 1994; 269: 10475-10484.
8. Gebhardt F, Zanker KS, Brandt B: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999; 274: 13176-13180.
9. Deal C, Ma J, Wilkin F et al: Novel promoter polymorphism in insulin-like growth factor-binding protein-3: Correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 2001; 86: 1274-1280.
10. Jernstrom H, Deal C, Wilkin F et al: Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001; 10: 377-384.
11. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD: Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 1204-1211.
12. Ren Z, Cai Q, Shu XO et al: Genetic polymorphisms in the IGFBP3 gene: Association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 2004; 13: 1290-1295.
13. Cleveland RJ, Gammon MD, Edmiston SN et al: IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis 2006; 27: 758-765.
14. Cox A, Dunning AM, Garcia-Closas M et al: A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007; 39: 352-358.
15. Wang L, Habuchi T, Tsuchiya N et al: Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 2003; 63 4407-4411.
16. Le Marchand L, Kolonel LN, Henderson BE, Wilkens LR: Association of an exon 1 polymorphism in the IGFBP3 gene with circulating IGFBP-3 levels and colorectal cancer risk: The multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2005; 14: 1319-1321.
17. Chen W, Wang L, Ke Q et al: The role of IGFBP3 functional polymorphisms in the risk of gastric cancer in a high-risk Chinese population. Eur J Cancer Prev 2008; 17: 82-87.
18. Fletcher O, Gibson L, Johnson N et al: Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: A systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 2-19.
19. Gonzalez-Zuloeta Ladd AM, Liu F, Houben MP et al: IGF-1 CA repeat variant and breast cancer risk in postmenopausal women. Eur J Cancer 2007; 43: 1718-1722.
20. Giovannucci E: Insulin, insulin-like growth factoAs and colon cancer: a review of the evidence. J Nutr 2001; 131: 3109S-3120S.
21. Morris JK, George LM, Wu T, Wald NJ: Insulin-like growth factors and cancer: No role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br J Cancer 2006; 95: 112-117.
22. Chen X, Guan J, Song Y et al: IGF-I (CA) repeat polymorphisms and risk of cancer: A meta-analysis. J Hum Genet 2008; 53: 227-238.
23. Lukanova A, Lundin E, Toniolo P et al: Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002; 101: 549-554.
24. Otani T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S: Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. Int J Cancer 2007; 120: 2007-2012.
25. Al-Zahrani A, Sandhu MS, Luben RN et al: IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 2006; 15: 1-10.
26. Rohrbacher M, Risch A, Kropp S, Chang-Claude J: The A(-336C) insulin-like growth factor binding protein-3 promoter polymorphism is not a modulator of breast cancer risk in Caucasian women. Cancer Epidemiol Biomarkers Prev 2005; 14: 289-290.
27. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
28. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22 719-748.
29. Deeks JJ: Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323 157-162.
30. Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-826.
31. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
32. Martin JL, Coverley JA, Pattison ST, Baxter RC: Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 1995; 136: 1219-1226.
33. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG: Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 1996; 56: 1545-1550.
34. Allen NE, Davey GK, Key TJ, Zhang S, Narod SA: Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-I gene. Cancer Epidemiol Biomarkers Prev 2002; 11: 319-320.
35. DeLellis K, Ingles S, Kolonel L et al: IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multi-ethnic cohort. Br J Cancer 2003; 88: 277-282.
36. Friedrichsen DM, Hawley S, Shu J et al: IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate 2005; 65 44-51.
37. Hernandez W, Grenade C, Santos ER, Bonilla C, Ahaghotu C, Kittles RA: IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans. Carcinogenesis 2007; 28: 2154-2159.
38. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN: Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 2003; 107 60-64.
39. Shi R, Yu H, McLartA J, Glass J: IGF-I and breast cancer: a meta-analysis. Int J Cancer 2004; 111: 418-423.
40. Sugumar A, Liu YC, Xia Q, Koh YS, Matsuo K: Insulin-like growth factor (IGF)-I and IGF-binding protein 3 and the risk of premenopausal breast cancer: A meta-analysis of literature. Int J Cancer 2004; 111 293-297.
41. Yee D, Lee AV: Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5: 107-115.
42. Clemons M, Goss P: Estrogen and the risk of breast cancer. N Engl J Med 2001; 344: 276-285.
43. McCaig C, Perks CM, Holly JM: Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: Inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci 2002; 115: 4293-4303.
44. Slattery ML, Baumgartner KB, Byers T et al: Genetic, anthropometric, and lifestyle factors associated with IGF-1 and IGFBP-3 levels in Hispanic and non-Hispanic white women. Cancer Causes Control 2005; 16: 1147-1157.
45. Papatsoris AG, Karamouzis MV, Papavassiliou AG: Novel insights into the implication of the IGF-1 network in prostate cancer. Trends Mol Med 2005; 11: 52-55.
46. Heinlein CA, Chang C: Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
47. Chan JM, Stampfer MJ, Ma J et al: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-1106.
48. Chokkalingam AP, Pollak M, Fillmore CM et al: Insulin-like growth factors and prostate cancer: A population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 2001; 10: 421-427.
49. Wolk A, Mantzoros CS, Andersson SO et al: Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-915.
50. Li L, Yu H, Schumacher F, Casey G, Witte JS: Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 2003; 14: 721-726.
51. Oliver SE, Holly J, Peters TJ et al: Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. Urology 2004; 64: 317-322.
52. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E: Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005; 16: 255-262.
53. Severi G, Morris HA, MacInnis RJ et al: Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1137-1141.
54. Allen NE, Key TJ, Appleby PN et al: Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: Results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007; 16 1121-1127.
55. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R: High levels of circulating insulin-like growth factor-I increase prostate cancer risk: A prospective study in a population-based nonscreened cohort. J Clin Oncol 2004; 22: 3104-3112.
56. Weiss JM, Huang WY, Rinaldi S et al: IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer 2007; 121: 2267-2273.
57. Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS: Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005; 103: 76-84.